Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT – 2)
Sponsor and Collaborators
Next post in Multiple Myeloma Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.